StockNews.com began coverage on shares of Milestone Scientific (NYSE:MLSS - Free Report) in a research report report published on Saturday. The firm issued a hold rating on the stock.
Separately, Benchmark initiated coverage on shares of Milestone Scientific in a research report on Thursday, October 10th. They set a "speculative buy" rating and a $1.25 target price on the stock.
Read Our Latest Analysis on Milestone Scientific
Milestone Scientific Price Performance
NYSE:MLSS traded up $0.01 during trading hours on Friday, hitting $0.81. 80,108 shares of the company traded hands, compared to its average volume of 73,173. The firm has a 50-day moving average of $0.91 and a 200 day moving average of $0.83. Milestone Scientific has a twelve month low of $0.52 and a twelve month high of $1.10.
Milestone Scientific (NYSE:MLSS - Get Free Report) last announced its quarterly earnings data on Thursday, August 15th. The company reported ($0.02) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.01). Milestone Scientific had a negative net margin of 54.87% and a negative return on equity of 60.78%. The company had revenue of $1.85 million for the quarter.
Insider Buying and Selling at Milestone Scientific
In other Milestone Scientific news, Director Leonard Osser sold 107,984 shares of the business's stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $0.93, for a total value of $100,425.12. Following the transaction, the director now directly owns 4,606,882 shares in the company, valued at $4,284,400.26. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders sold 251,106 shares of company stock valued at $236,451. 24.75% of the stock is currently owned by company insiders.
About Milestone Scientific
(
Get Free Report)
Milestone Scientific Inc, a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments.
Read More
Before you consider Milestone Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Milestone Scientific wasn't on the list.
While Milestone Scientific currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
